Bitolterol

Summary

Bitolterol (CHEMBL1201295) is an approved small-molecule bronchodilator agent (ATC R03AC17); indicated across 1 condition including obstructive lung disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R03AC17
• Indications: 1 condition
• Chemistry: 461.5 Da · C28H31NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201295
Name	Bitolterol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	35330
ChEBI	CHEBI:3133
ATC	R03AC17
Molecular formula	C28H31NO5
Molecular weight	461.5
InChIKey	FZGVEKPRDOIXJY-UHFFFAOYSA-N

SMILES: CC1=CC=C(C=C1)C(=O)OC2=C(C=C(C=C2)C(CNC(C)(C)C)O)OC(=O)C3=CC=C(C=C3)C

IUPAC name: [4-[2-(tert-butylamino)-1-hydroxyethyl]-2-(4-methylbenzoyl)oxyphenyl] 4-methylbenzoate

ChEBI definition: The di-4-toluate ester of (±)-N-tert-butylnoradrenaline (colterol). A pro-drug for colterol, a β2-adrenergic receptor agonist, bitolterol is used as its methanesulfonate salt for relief of bronchospasm in conditions such as asthma, chronic bronchitis and emphysema.

Pharmacological roles (ChEBI): bronchodilator agent, anti-asthmatic drug, β-adrenergic agonist, prodrug.

Also known as: Bitolterol, SID170465239, BITOLTEROL

Parent form; salt/anhydrous children: CHEMBL1200405

Patent coverage: 2,541 distinct patent families (10,843 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 10,789 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obstructive lung disease	4	MONDO:0002267	HP:0006536

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).